US4935465A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Conjugates of pharmaceutically useful proteins
Assignee: Adprotech PLC
•
Filing: 1985-11-27
•
Granted: 1990-06-19
•
Expires: 2005-11-27
Abstract
Abstract A conjugate comprising a pharmaceutically useful protein linked to at least one water-soluble polymer by means of a reversible linking group.
Inventors
- 👤 Andrew J. Garman
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 11:38
CPC Classifications
A; A61; A61K; A61K38/00; A61K38/16; A61K38/43; A61K38/46; A61K38/48; A61K38/49; A61K38/17; A61K38/38; A61K47/00; A61K47/50; A61K47/51; A61K47/56; A61K47/59; A61K47/60
Claims Analysis
Total Claims: 10
Claim 1
Independent Claim
208 words
A conjugate of formula (II): ##STR12## where X is a pharmaceutically useful protein and the NH moiety is derived from a protein amino group in X; and either: (i) R1 and R 2 are each a non-polymeric organic group or a group of formula --R 3 --P wherein P is a water-soluble polymer selected from the group consisting of polyethylene glycol, polypropylene glycol and methoxy polyethylene glycol and R 3 is a bridging group selected from the group consisting of straight or branched C 1-10 aliphatic hydrocarbon chains and straight or branched C 1-10 aliphatic hydrocarbon chains interrupted or terminated by an amide moiety, an ester moiety or at least one hetero atom selected from oxygen, sulphur or nitrogen, said moiety being unsubstituted or substituted by C 1-16 alkyl; or (ii) R 1 and R 2 together are C 3-5 polymethylene to complete a 5- to 7-membered alicyclic ring or together complete an aromatic ring, wherein the alicyclic or aromatic ring is substituted by groups R 4 and R 5 which are each of non-polymeric organic group or a group of formula --R 3 --P; provided that at lease one of RI and R 2 or of R 4 and R 5 is a group --R 3 --P.
Claim 2
Dependent Claim
208 words
A conjugate of formula (II): ##STR12## where X is a pharmaceutically useful protein and the NH moiety is derived from a protein amino group in X; and either: (i) R1 and R 2 are each a non-polymeric organic group or a group of formula --R 3 --P wherein P is a water-soluble polymer selected from the group consisting of polyethylene glycol, polypropylene glycol and methoxy polyethylene glycol and R 3 is a bridging group selected from the group consisting of straight or branched C 1-10 aliphatic hydrocarbon chains and straight or branched C 1-10 aliphatic hydrocarbon chains interrupted or terminated by an amide moiety, an ester moiety or at least one hetero atom selected from oxygen, sulphur or nitrogen, said moiety being unsubstituted or substituted by C 1-16 alkyl; or (ii) R 1 and R 2 together are C 3-5 polymethylene to complete a 5- to 7-membered alicyclic ring or together complete an aromatic ring, wherein the alicyclic or aromatic ring is substituted by groups R 4 and R 5 which are each of non-polymeric organic group or a group of formula --R 3 --P; provided that at lease one of RI and R 2 or of R 4 and R 5 is a group --R 3 --P.
Claim 3
Dependent Claim
19 words
A conjugate according to claim 1 in which the pharmaceutically useful protein is a fibrinolytic enzyme or pro-enzyme thereof.
Claim 4
Dependent Claim
24 words
A conjugate according to claim 1, wherein one of R 1 and R 2 is a group P--CH 2 --and the other is methyl.
Claim 5
Dependent Claim
14 words
A conjugate according to claim 1, wherein the water soluble polymer is methoxypolyethylene glycol.
Claim 6
Dependent Claim
17 words
A conjugate according to claim 1, wherein the pharmaceutically useful protein is tissue plasminogen activator or urokinase.
Claim 7
Dependent Claim
45 words
A process for preparing a conjugate according to claim 1 which process comprises reacting a pharmaceutically useful protein with a water-soluble polymer-containing regent comprising a group which is capable of reacting with a protein amino group or derivative thereof, to form a reversible linking group.
Claim 8
Dependent Claim
43 words
A conjugate according to claim 1, wherein PR 3 --is P(CH 2 ) n --, PO(CH 2 ) n O--, P(CH 3 )CH--, P(CH 3 ) 2 C--, PO(CH 3 )CH-- or PO(CH 3 ) 2 C-- where n is 1 to 6.
Claim 9
Dependent Claim
17 words
2[ω-MethoxypolyethyIeneglycoxymethylene]-3-methylmaleyl-human serum albumin, 2-methyl-3-[ω-methoxypolyethyleneglycoxy-methylene]-maleyl-human serum albumin, [ω -methoxypolyethyleneglycoxymethylene]-3-methylmaleyl-urokinase, 2-methyl-3-[ω-methoxypolyethyleneglycoxy-methylene]-maleyl-urokinase, 2-[ω-methoxypolyethyleneglycoxymethylene]-3- methyl-maleyl-tissue plasminogen activator or 2-methyl-3-[ω-methoxypolyethylenegIycoxy-methylene]-maleyl-tissue plasminogen activator.
Claim 10
Dependent Claim
17 words
2[ω-MethoxypolyethyIeneglycoxymethylene]-3-methylmaleyl-human serum albumin, 2-methyl-3-[ω-methoxypolyethyleneglycoxy-methylene]-maleyl-human serum albumin, [ω -methoxypolyethyleneglycoxymethylene]-3-methylmaleyl-urokinase, 2-methyl-3-[ω-methoxypolyethyleneglycoxy-methylene]-maleyl-urokinase, 2-[ω-methoxypolyethyleneglycoxymethylene]-3- methyl-maleyl-tissue plasminogen activator or 2-methyl-3-[ω-methoxypolyethylenegIycoxy-methylene]-maleyl-tissue plasminogen activator.
References Cited (Backward Citations)
GB1059670A
Cited
GB1390716A
Cited
US4055635A
Cited
US4179337A
Cited
EP0038154A1
Cited
US4640835A
Cited
FR2515684A1
Cited
EP0098110A2
Cited
US4496689A
Cited
US4542225A
Cited
US4569789A
Cited
US4618492A
Cited
US4764368A
Cited
US4863735A
Cited
US4859736A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1993-06-18 | 1993-12-18 | 1994-06-19 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1997-06-18 | 1997-12-18 | 1998-06-19 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2001-06-18 | 2001-12-18 | 2002-06-19 | $7700.00 | Window Closed / Lapsed |